Cargando…
Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection
Phage-derived therapies comprise phage therapy and the use of phage-derived proteins as anti-bacterial therapy. Bacteriophages are natural viruses that target specific bacteria. They were proposed to be used to treat bacterial infections in the 1920s, before the discovery and widespread over-commerc...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708067/ https://www.ncbi.nlm.nih.gov/pubmed/34960683 http://dx.doi.org/10.3390/v13122414 |
_version_ | 1784622591241093120 |
---|---|
author | Ferry, Tristan Kolenda, Camille Briot, Thomas Souche, Aubin Lustig, Sébastien Josse, Jérôme Batailler, Cécile Pirot, Fabrice Medina, Mathieu Leboucher, Gilles Laurent, Frédéric |
author_facet | Ferry, Tristan Kolenda, Camille Briot, Thomas Souche, Aubin Lustig, Sébastien Josse, Jérôme Batailler, Cécile Pirot, Fabrice Medina, Mathieu Leboucher, Gilles Laurent, Frédéric |
author_sort | Ferry, Tristan |
collection | PubMed |
description | Phage-derived therapies comprise phage therapy and the use of phage-derived proteins as anti-bacterial therapy. Bacteriophages are natural viruses that target specific bacteria. They were proposed to be used to treat bacterial infections in the 1920s, before the discovery and widespread over-commercialized use of antibiotics. Phage therapy was totally abandoned in Western countries, whereas it is still used in Poland, Georgia and Russia. We review here the history of phage therapy by focusing on bone and joint infection, and on the development of phage therapy in France in this indication. We discuss the rationale of its use in bacterial infection and show the feasibility of phage therapy in the 2020s, based on several patients with complex bone and joint infection who recently received phages as compassionate therapy. Although the status of phage therapy remains to be clarified by health care authorities, obtaining pharmaceutical-grade therapeutic phages (i.e., following good manufacturing practice guidelines or being “GMP-like”) targeting bacterial species of concern is essential. Moreover, multidisciplinary clinical expertise has to determine what could be the relevant indications to perform clinical trials. Finally “phage therapy 2.0” has to integrate the following steps: (i) follow the status of phage therapy, that is not settled and defined; (ii) develop in each country a close relationship with the national health care authority; (iii) develop industrial–academic partnerships; (iv) create academic reference centers; (v) identify relevant clinical indications; (vi) use GMP/GMP-like phages with guaranteed quality bioproduction; (vii) start as salvage therapy; (vii) combine with antibiotics and adequate surgery; and (viii) perform clinical trials, to finally (ix) demonstrate in which clinical settings phage therapy provides benefit. Phage-derived proteins such as peptidoglycan hydrolases, polysaccharide depolymerases or lysins are enzymes that also have anti-biofilm activity. In contrast to phages, their development has to follow the classical process of medicinal products. Phage therapy and phage-derived products also have a huge potential to treat biofilm-associated bacterial diseases, and this is of crucial importance in the worldwide spread of antimicrobial resistance. |
format | Online Article Text |
id | pubmed-8708067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87080672021-12-25 Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection Ferry, Tristan Kolenda, Camille Briot, Thomas Souche, Aubin Lustig, Sébastien Josse, Jérôme Batailler, Cécile Pirot, Fabrice Medina, Mathieu Leboucher, Gilles Laurent, Frédéric Viruses Review Phage-derived therapies comprise phage therapy and the use of phage-derived proteins as anti-bacterial therapy. Bacteriophages are natural viruses that target specific bacteria. They were proposed to be used to treat bacterial infections in the 1920s, before the discovery and widespread over-commercialized use of antibiotics. Phage therapy was totally abandoned in Western countries, whereas it is still used in Poland, Georgia and Russia. We review here the history of phage therapy by focusing on bone and joint infection, and on the development of phage therapy in France in this indication. We discuss the rationale of its use in bacterial infection and show the feasibility of phage therapy in the 2020s, based on several patients with complex bone and joint infection who recently received phages as compassionate therapy. Although the status of phage therapy remains to be clarified by health care authorities, obtaining pharmaceutical-grade therapeutic phages (i.e., following good manufacturing practice guidelines or being “GMP-like”) targeting bacterial species of concern is essential. Moreover, multidisciplinary clinical expertise has to determine what could be the relevant indications to perform clinical trials. Finally “phage therapy 2.0” has to integrate the following steps: (i) follow the status of phage therapy, that is not settled and defined; (ii) develop in each country a close relationship with the national health care authority; (iii) develop industrial–academic partnerships; (iv) create academic reference centers; (v) identify relevant clinical indications; (vi) use GMP/GMP-like phages with guaranteed quality bioproduction; (vii) start as salvage therapy; (vii) combine with antibiotics and adequate surgery; and (viii) perform clinical trials, to finally (ix) demonstrate in which clinical settings phage therapy provides benefit. Phage-derived proteins such as peptidoglycan hydrolases, polysaccharide depolymerases or lysins are enzymes that also have anti-biofilm activity. In contrast to phages, their development has to follow the classical process of medicinal products. Phage therapy and phage-derived products also have a huge potential to treat biofilm-associated bacterial diseases, and this is of crucial importance in the worldwide spread of antimicrobial resistance. MDPI 2021-12-02 /pmc/articles/PMC8708067/ /pubmed/34960683 http://dx.doi.org/10.3390/v13122414 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ferry, Tristan Kolenda, Camille Briot, Thomas Souche, Aubin Lustig, Sébastien Josse, Jérôme Batailler, Cécile Pirot, Fabrice Medina, Mathieu Leboucher, Gilles Laurent, Frédéric Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title | Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title_full | Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title_fullStr | Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title_full_unstemmed | Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title_short | Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection |
title_sort | past and future of phage therapy and phage-derived proteins in patients with bone and joint infection |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708067/ https://www.ncbi.nlm.nih.gov/pubmed/34960683 http://dx.doi.org/10.3390/v13122414 |
work_keys_str_mv | AT ferrytristan pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT kolendacamille pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT briotthomas pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT soucheaubin pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT lustigsebastien pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT jossejerome pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT bataillercecile pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT pirotfabrice pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT medinamathieu pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT lebouchergilles pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT laurentfrederic pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection AT pastandfutureofphagetherapyandphagederivedproteinsinpatientswithboneandjointinfection |